Shares of Renalytix Plc (LON:RENX – Get Free Report) traded down 1.6% during trading on Tuesday . The company traded as low as GBX 1.80 and last traded at GBX 1.87. Approximately 194,919 shares were traded during trading, a decline of 77% from the average daily volume of 834,957 shares. The stock had previously closed at GBX 1.90.
Renalytix Stock Down 1.6%
The company’s 50 day moving average price is GBX 1.82 and its two-hundred day moving average price is GBX 3.62. The firm has a market cap of £8.17 million, a PE ratio of -0.47 and a beta of 1.81. The company has a current ratio of 1.21, a quick ratio of 2.42 and a debt-to-equity ratio of -118.57.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Articles
- Five stocks we like better than Renalytix
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
